Medical Therapy with Pasireotide in Recurrent Cushing’s Disease: Experience of Patients Treated for At Least 1 Year at a Single Center

Subcutaneous (SC) injection of pasireotide, a somatostatin analog, is approved for the treatment of adults with Cushing’s disease (CD) for whom pituitary surgery was unsuccessful or is not an option. We highlight the symptomatic and biochemical improvement of six patients with recurrent CD treated w...

Descripción completa

Detalles Bibliográficos
Autores principales: Yedinak, Chris G., Hopkins, Sarah, Williams, Jessica, Ibrahim, Aly, Cetas, Justin Schultz, Fleseriu, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327352/
https://www.ncbi.nlm.nih.gov/pubmed/28289402
http://dx.doi.org/10.3389/fendo.2017.00035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327352/
https://www.ncbi.nlm.nih.gov/pubmed/28289402
http://dx.doi.org/10.3389/fendo.2017.00035

Ejemplares similares